{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:25:28Z","timestamp":1787682328870,"version":"build-2784847793"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1124\/jpet.122.001362","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T16:45:12Z","timestamp":1675701912000},"page":"50-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation"],"prefix":"10.1016","volume":"385","author":[{"given":"Kamal P.","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Divovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjana","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit K.","family":"Golani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M.","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Jean","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leggy A.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dishary","family":"Sharmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yeunus","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.N. Phani Babu","family":"Tiruveedhula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav M.","family":"Savi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001362_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1124\/jpet.122.001362_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001362_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172996","article-title":"The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","volume":"196","author":"Biggerstaff","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4522(98)00401-1","article-title":"Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy","volume":"89","author":"Bouilleret","year":"1999","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.122.001362_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108035","article-title":"GABAkines - advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors","volume":"234","author":"Cerne","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.122.001362_bib6","series-title":"The Neurobiology, Physiology, and Psychology of Pain","first-page":"117","article-title":"The orally bioavailable imidazodiazepine, KRM-II-81, is a novel potentiator of \u03b12\/3-containing GABAA receptors with analgesic efficacy","author":"Cerne","year":"2022"},{"key":"10.1124\/jpet.122.001362_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-2999(78)90330-8","article-title":"Benzodiazepine receptors: labeling in intact animals with [3H] flunitrazepam","volume":"48","author":"Chang","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001362_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0920-1211(97)01035-8","article-title":"Decreased density of lymphocyte benzodiazepine receptors in drug-resistant epileptic patients","volume":"27","author":"Ferrarese","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1124\/jpet.122.001362_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.physbeh.2018.08.025","article-title":"The role of 5-HT1A receptors of hippocampal CA1 region in anticonvulsant effects of low-frequency stimulation in amygdala kindled rats","volume":"196","author":"Gharib","year":"2018","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.122.001362_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/bdd.2313","article-title":"Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the \u03b12\/3-selective GABAkine KRM-II-81","volume":"43","author":"Golani","year":"2022","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.122.001362_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128637","article-title":"Rationalizing the binding and \u03b1 subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies","volume":"62","author":"Golani","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.122.001362_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0091-3057(79)90125-4","article-title":"Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors","volume":"11","author":"Klepner","year":"1979","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib13","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acschemneuro.0c00295","article-title":"Imidazodiazepine anticonvulsant, KRM-II-81, produces novel, non-diazepam-like antiseizure effects","volume":"11","author":"Knutson","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.122.001362_bib14","doi-asserted-by":"crossref","first-page":"27550","DOI":"10.1021\/acsomega.2c03029","article-title":"Hydrochloride salt of the GABAkine KRM-II-81","volume":"7","author":"Mian","year":"2022","journal-title":"ACS Omega"},{"key":"10.1124\/jpet.122.001362_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eplepsyres.2014.02.013","article-title":"Low potency and limited efficacy of antiepileptic drugs in the mouse 6 Hz corneal kindling model","volume":"108","author":"Leclercq","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1124\/jpet.122.001362_bib16","series-title":"Characterization of novel \u03b12\/\u03b13 subtype-selective GABAA receptor positive allosteric modulators.","author":"Lewter","year":"2019"},{"key":"10.1124\/jpet.122.001362_bib17","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1055\/s-0037-1610211","article-title":"Improved synthesis of anxiolytic, anticonvulsant and antinociceptive \u03b12\/\u03b13-GABA(A)ergic receptor subtype selective ligands as promising agents to treat anxiety, epilepsy, as well as neuropathic pain","volume":"50","author":"Li","year":"2018","journal-title":"Synthesis (Stuttg)"},{"key":"10.1124\/jpet.122.001362_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"10.1124\/jpet.122.001362_bib19","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/0024-3205(81)90498-7","article-title":"Differential ontogeny of type 1 and type 2 benzodiazepine receptors","volume":"28","author":"Lippa","year":"1981","journal-title":"Life Sci"},{"key":"10.1124\/jpet.122.001362_bib20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0091-3057(78)90368-4","article-title":"Relationship between benzodiazepine receptors and experimental anxiety in rats","volume":"9","author":"Lippa","year":"1978","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0024-3205(82)90001-7","article-title":"Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors","volume":"31","author":"Lippa","year":"1982","journal-title":"Life Sci"},{"key":"10.1124\/jpet.122.001362_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/brain\/awl384","article-title":"Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors","volume":"130","author":"Loacker","year":"2007","journal-title":"Brain"},{"key":"10.1124\/jpet.122.001362_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0091-3057(03)00218-1","article-title":"Studies on the anticonvulsant effect of U50488H on maximal electroshock seizure in mice","volume":"76","author":"Manocha","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","article-title":"GABAA receptor signalling mechanisms revealed by structural pharmacology","volume":"565","author":"Masiulis","year":"2019","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001362_bib25","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/cpph.43","article-title":"The Irwin test and functional observational battery (FOB) for assessing the effects of compounds on behavior, physiology, and safety pharmacology in rodents","volume":"83","author":"Mathiasen","year":"2018","journal-title":"Curr Protocols Pharmacol"},{"key":"10.1124\/jpet.122.001362_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pbb.2018.04.009","article-title":"An antidepressant-related pharmacological signature for positive allosteric modulators of \u03b12\/3-containing GABAA receptors","volume":"170","author":"Methuku","year":"2018","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/FBP.0000000000000464","article-title":"Effects of the \u03b12\/\u03b13-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam","volume":"30","author":"Moerke","year":"2019","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.122.001362_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.brainres.2014.01.036","article-title":"Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects","volume":"1554","author":"Obradovi\u0107","year":"2014","journal-title":"Brain Res"},{"key":"10.1124\/jpet.122.001362_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.24820\/ark.5550190.p011.398","article-title":"Design, synthesis and characterization of novel gamma-aminobutyric acid type A receptor ligands","volume":"2020","author":"Pandey","year":"2020","journal-title":"ARKIVOC"},{"key":"10.1124\/jpet.122.001362_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.yebeh.2017.04.045","article-title":"Assessing the role of serotonergic receptors in cannabidiol\u2019s anticonvulsant efficacy","volume":"73","author":"Pelz","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1124\/jpet.122.001362_bib31A","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22042","article-title":"Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog","author":"Ping","year":"2023","journal-title":"Drug development research"},{"key":"10.1124\/jpet.122.001362_bib31","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel \u03b3-aminobutyric acid type A (GABAA) receptor ligand that combines outstanding metabolic stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001362_bib32","series-title":"Design and Synthesis of Achiral and Chiral Benzodiazepines and Imidazodiazepines to Modulate the Activity of GABAA Receptors for the Treatment of Cancer, CNS Disorders and Pain.","author":"Rashid","year":"2021"},{"key":"10.1124\/jpet.122.001362_bib33","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/jm801652d","article-title":"Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models","volume":"52","author":"Rivas","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001362_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.pharep.2014.02.014","article-title":"Evaluation of anticonvulsant activity of novel pyrrolidin-2-one derivatives","volume":"66","author":"Sapa","year":"2014","journal-title":"Pharmacol Rep"},{"key":"10.1124\/jpet.122.001362_bib35","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1021\/acs.jmedchem.8b01453","article-title":"Halogens in protein-ligand binding mechanism: a structural perspective","volume":"62","author":"Shinada","year":"2019","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001362_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0006-8993(00)01971-5","article-title":"Anticonvulsant actions of nefiracetam on epileptic EL mice and their relation to peripheral-type benzodiazepine receptors","volume":"859","author":"Shiotani","year":"2000","journal-title":"Brain Res"},{"key":"10.1124\/jpet.122.001362_bib37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(83)90579-4","article-title":"Properties of [3H]flunitrazepam binding to different benzodiazepine binding proteins","volume":"88","author":"Sieghart","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001362_bib38","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1016\/j.bmc.2015.06.045","article-title":"N-[(2,6-dimethylphenoxy)alkyl]aminoalkanols-their physicochemical and anticonvulsant properties","volume":"23","author":"Waszkielewicz","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"0 4, Suppl 4","key":"10.1124\/jpet.122.001362_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/epi.12296","article-title":"Issues related to development of new antiseizure treatments","volume":"54","author":"Wilcox","year":"2013","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.122.001362_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2017.04.009","article-title":"Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for \u03b12\/3-containing GABAA receptors","volume":"157","author":"Witkin","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.119.260968","article-title":"The positive allosteric modulator of \u03b1 2\/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury","volume":"372","author":"Witkin","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001362_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173321","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","volume":"213","author":"Witkin","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.122.001362_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuropharm.2018.05.006","article-title":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy","volume":"137","author":"Witkin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001362_bib44","first-page":"97","article-title":"Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern","volume":"92","author":"Woodbury","year":"1952","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1124\/jpet.122.001362_bib45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/164_2021_444","article-title":"The kappa opioid receptor system in temporal lobe epilepsy","volume":"271","author":"Zangrandi","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.122.001362_bib46","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1021\/acs.jmedchem.0c01720","article-title":"Intestinal excretion, intestinal recirculation, and renal tubule reabsorption are underappreciated mechanisms that drive the distribution and pharmacokinetic behavior of small molecule drugs","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:28:30Z","timestamp":1739971710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524004269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0022356524004269"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001362","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}